Business
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
BOSTON, April 23, 2026--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced today that the company will present data from its LANDMARK survey during the 2026 Digestive Disease Week® (DDW) meeting being held from May 2-5 in Chicago, IL. The data will spotlight healthcare professional (HCP) insights on the burden of total parenteral nutrition (TPN) for
About this update from Ironwood Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":251,"url":"https://media.zenfs.com/en/business-wire.com/3544a8aed8688ae45137216396dbfa69"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kJZVZ6_79knMHdzyNf.eJA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwMg--/https://media.zenfs.com/en/business-wire.com/3544a8aed8688ae45137216396dbfa69","width":480,"height":251}},"lazy":false},{"type":"text","content":"– Separate poster will feature long-term safety and tolerability data from STARS clinical trial program of apraglutide in adults with SBS who are dependent on parenteral support (PS) –","length":184,"tagName":"p","attribs":{}},{"type":"text","content":"– Linaclotide data presentations highlight efficacy and safety insights in IBS-C, CIC and pediatric FC –","length":104,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, April 23, 2026--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced today that the company will present data from its LANDMARK survey during the 2026 Digestive Disease Week® (DDW) meeting being held from May 2-5 in Chicago, IL. The data will spotlight healthcare professional (HCP) insights on the burden of total parenteral nutrition (TPN) for patients with short bowel syndrome (SBS), as well as preferred attributes for potential new therapies that reduce TPN dependence.","length":647,"tagName":"p"},{"type":"text","content":"SBS is a serious and chronic condition characterized by reduced absorptive capacity for fluids and/or nutrients, often requiring long-term dependence on parenteral support (PS) (IV nutrition and/or IV hydration) to sustain life. Patients with SBS who are chronically dependent on PS, also referred to as SBS with intestinal failure (SBS-IF), frequently experience significant treatment burden, reduced quality of life and increased risk of severe complications such as infection. Despite current management approaches, substantial unmet need remains for therapies that reduce PS dependence and improve outcomes. An estimated 18,000 adult patients suffer from SBS-IF in the U.S., Europe and Japan, and have chronic dependence on PS.","length":7...